OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study

OVM-200 vaccination in 27 patients with advanced non-small cell lung, ovarian, or prostate cancer induced robust survivin-specific immunity, peaking at 81,920 IgG titres.

• Why it matters: Survivin (BIRC5) is a self-antigen in many cancers, and immune tolerance limits spontaneous antitumour responses. This study addresses whether a designed vaccine can overcome that tolerance in patients with advanced solid tumours.
• What they did: In a multicentre, open-label phase 1 dose-expansion study at 4 UK sites, OVM-200-100 was given subcutaneously every 2 weeks for 3 initial vaccinations, with up to 8 additional doses. Survivin-specific humoral and cellular responses were measured by IgG titres and interferon-gamma ELISpot.
• The result: All OVM-200-related adverse events were grade 1–2 with no treatment-related grade ≥3 events, dose-limiting toxicities, serious adverse events, or deaths. Among 24 RECIST-evaluable patients, stable disease occurred in 6 (25%), and higher anti-survivin antibody titres were linked to stable disease versus progressive disease (p=0.0418).

AI summary of the abstract · may contain errors · not medical advice · read the paper.